Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasatinib - Bristol-Myers Squibb

Drug Profile

Dasatinib - Bristol-Myers Squibb

Alternative Names: BMS-354825; Sprycel

Latest Information Update: 29 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Massachusetts General Hospital; Otsuka Pharmaceutical; Sarcoma Alliance for Research through Collaboration; University of Texas M. D. Anderson Cancer Center; Weill Cornell Medical College
  • Class Amides; Antineoplastics; Chlorobenzenes; Piperazines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase III Prostate cancer
  • Phase II Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Myeloproliferative disorders; Sarcoma
  • Phase I/II Glioblastoma; Non-Hodgkin's lymphoma
  • No development reported Colorectal cancer; Leukaemia; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-small cell lung cancer
  • Discontinued Pancreatic cancer; Scleroderma

Most Recent Events

  • 13 Jun 2019 Updated two-year efficacy and adverse events data from the phase II DASFREE trial in Chronic myeloid leukaemia presented at the 24th Congress of the European Haematology Association
  • 30 May 2019 Boehringer Ingelheim, Bristol-Myers Squibb and H. Lee Moffitt Cancer Center and Research Institute completes a phase I trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Recurrent, Metastatic, Inoperable/unresectable) in USA (PO) (NCT01999985)
  • 11 Feb 2019 Registered for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, First-line therapy, In adolescents, In children, Newly diagnosed, In infants) in Norway, Iceland, Liechtenstein (PO, Suspension and Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top